The challenge
Our client, a specialized biopharmaceutical company dedicated to developing treatments for rare diseases, sought to navigate the challenge of lengthy traditional access pathways.
The client asked Inbeeo to comprehensively explore potential early and alternative access pathways across Europe, MENAT, LATAM, APAC, and North America, to accelerate patient access, particularly in rare diseases with high unmet needs.
The key objective was to provide guidance to the client when identifying relevant early / alternative access pathways for its assets.
The approach
Inbeeo developed a catalogue of almost 100 early and alternative access pathways in 62 markets across the 5 regions.
The catalogue was based on extensive secondary research into 5 clearly delineated types of early and alternative access pathways. For each pathway, a 1-slide detailed description was provided.
The catalogue was easy to navigate, based on an executive summary that allowed for rapid identification of relevant pathways, based on e.g. the earliest possible start of the program, funding sources, patient volume, accessibility, opportunities, and risks.
The impact
Inbeeo’s output informed future market access strategies and streamlined the decision-making process for expedited patient access in the face of challenging traditional pathways.
